Literature DB >> 11486901

Plasma phenylalanine is associated with decreased serum ubiquinone-10 concentrations in phenylketonuria.

R Artuch1, C Colomé, M A Vilaseca, C Sierra, F J Cambra, N Lambruschini, J Campistol.   

Abstract

Decreased serum ubiquinone-10 concentrations is a common condition in patients with phenylketonuria (PKU) under dietary treatment. Our aim was to investigate the implication of the metabolic abnormalities of PKU (low concentrations of tyrosine and high concentrations of phenylalanine) and the effect of treatment with phenylalanine-restricted diets in decreased ubiquinone-10 concentrations in PKU patients. We studied 30 PKU patients (age range 5 months to 35 years; median age 7 years) under dietary treatment. Correlation between plasma tyrosine or phenylalanine and serum ubiquinone-10 concentrations was investigated. Daily cholesterol intake was calculated from the data obtained through a dietary questionnaire. The index of dietary control (IDC) was calculated as the average of the medians of plasma phenylalanine concentrations obtained every 6 months in the metabolic control of patients. Negative correlations were observed between serum ubiquinone and the IDC (r=-0.46; p<0.01) in PKU patients. No correlation was observed between tyrosine or daily cholesterol intake and serum ubiquinone concentrations. After adjustment for daily cholesterol intake by multiple linear regression analysis, for each 113 units of increase in IDC values serum ubiquinone decreased 0.1 micromol/L. According to our results, the main factor associated with the decreased serum ubiquinone concentrations was high plasma phenylalanine values. Although daily cholesterol intake seems to be associated with ubiquinone concentrations, it may not be relevant if we take into account the low intake of cholesterol in treated PKU patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11486901     DOI: 10.1023/a:1010500502275

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  16 in total

1.  Serum ubiquinone-10 in a pediatric population.

Authors:  R Artuch; J Moreno; M Quintana; R M Puig; M A Vilaseca
Journal:  Clin Chem       Date:  1998-11       Impact factor: 8.327

Review 2.  Coenzyme Q deficiency in mitochondria: kinetic saturation versus physical saturation.

Authors:  G Lenaz; G Parenti Castelli; M D'Aurelio; C Bovina; G Formiggini; M Marchetti; E Estornell; H Rauchova
Journal:  Mol Aspects Med       Date:  1997

3.  Decreased serum ubiquinone-10 concentrations in phenylketonuria.

Authors:  R Artuch; M A Vilaseca; J Moreno; N Lambruschini; F J Cambra; J Campistol
Journal:  Am J Clin Nutr       Date:  1999-11       Impact factor: 7.045

Review 4.  The essential functions of coenzyme Q.

Authors:  F L Crane; I L Sun; E E Sun
Journal:  Clin Investig       Date:  1993

5.  Is there a relationship between 3-hydroxy-3-methylglutaryl coenzyme a reductase activity and forebrain pathology in the PKU mouse?

Authors:  S Shefer; G S Tint; D Jean-Guillaume; E Daikhin; A Kendler; L B Nguyen; M Yudkoff; C A Dyer
Journal:  J Neurosci Res       Date:  2000-09-01       Impact factor: 4.164

6.  Mitochondrial encephalomyopathy with coenzyme Q10 deficiency.

Authors:  C Sobreira; M Hirano; S Shanske; R K Keller; R G Haller; E Davidson; F M Santorelli; A F Miranda; E Bonilla; D S Mojon; A A Barreira; M P King; S DiMauro
Journal:  Neurology       Date:  1997-05       Impact factor: 9.910

7.  Ubiquinol-10 protects human low density lipoprotein more efficiently against lipid peroxidation than does alpha-tocopherol.

Authors:  R Stocker; V W Bowry; B Frei
Journal:  Proc Natl Acad Sci U S A       Date:  1991-03-01       Impact factor: 11.205

8.  Large daily fluctuations in plasma tyrosine in treated patients with phenylketonuria.

Authors:  F J van Spronsen; T van Dijk; G P Smit; M van Rijn; D J Reijngoud; R Berger; H S Heymans
Journal:  Am J Clin Nutr       Date:  1996-12       Impact factor: 7.045

Review 9.  Biochemical, physiological and medical aspects of ubiquinone function.

Authors:  L Ernster; G Dallner
Journal:  Biochim Biophys Acta       Date:  1995-05-24

10.  Neurological outcome in adult patients with early-treated phenylketonuria.

Authors:  J Pietz; R Dunckelmann; A Rupp; D Rating; H M Meinck; H Schmidt; H J Bremer
Journal:  Eur J Pediatr       Date:  1998-10       Impact factor: 3.183

View more
  11 in total

Review 1.  Oxidative stress in phenylketonuria: what is the evidence?

Authors:  Graziela S Ribas; Angela Sitta; Moacir Wajner; Carmen R Vargas
Journal:  Cell Mol Neurobiol       Date:  2011-04-23       Impact factor: 5.046

2.  PKU is a reversible neurodegenerative process within the nigrostriatum that begins as early as 4 weeks of age in Pah(enu2) mice.

Authors:  Jennifer E Embury; Catherine E Charron; Anatoly Martynyuk; Andreas G Zori; Bin Liu; Syed F Ali; Neil E Rowland; Philip J Laipis
Journal:  Brain Res       Date:  2006-11-15       Impact factor: 3.252

Review 3.  Oxidative stress in phenylketonuria: future directions.

Authors:  Júlio César Rocha; Maria João Martins
Journal:  J Inherit Metab Dis       Date:  2011-11-25       Impact factor: 4.982

4.  Effect of Blood Phenylalanine Levels on Oxidative Stress in Classical Phenylketonuric Patients.

Authors:  Burcu Kumru; Davut Sinan Kaplan; Burcu Oztürk Hismi; Hakim Celik
Journal:  Cell Mol Neurobiol       Date:  2017-12-28       Impact factor: 5.046

5.  Evidence that L-carnitine and selenium supplementation reduces oxidative stress in phenylketonuric patients.

Authors:  A Sitta; C S Vanzin; G B Biancini; V Manfredini; A B de Oliveira; C A Y Wayhs; G O S Ribas; L Giugliani; I V D Schwartz; D Bohrer; S C Garcia; M Wajner; C R Vargas
Journal:  Cell Mol Neurobiol       Date:  2010-12-30       Impact factor: 5.046

6.  Blood mononuclear cell coenzyme Q10 concentration and mitochondrial respiratory chain succinate cytochrome-c reductase activity in phenylketonuric patients.

Authors:  I P Hargreaves; S J R Heales; A Briddon; J M Land; P J Lee
Journal:  J Inherit Metab Dis       Date:  2002-12       Impact factor: 4.982

7.  Glutathione metabolism enzymes in brain and liver of hyperphenylalaninemic rats and the effect of lipoic acid treatment.

Authors:  Tarsila Barros Moraes; Giovana Reche Dalazen; Carlos Eduardo Jacques; Raylane Silva de Freitas; Andrea Pereira Rosa; Carlos Severo Dutra-Filho
Journal:  Metab Brain Dis       Date:  2014-02-02       Impact factor: 3.584

Review 8.  Oxidative stress in phenylketonuria-evidence from human studies and animal models, and possible implications for redox signaling.

Authors:  Vanessa Trindade Bortoluzzi; Carlos Severo Dutra Filho; Clovis Milton Duval Wannmacher
Journal:  Metab Brain Dis       Date:  2021-02-13       Impact factor: 3.584

9.  Assessment of mitochondrial respiratory chain function in hyperphenylalaninaemia.

Authors:  N Kyprianou; E Murphy; P Lee; I Hargreaves
Journal:  J Inherit Metab Dis       Date:  2009-03-13       Impact factor: 4.982

10.  Status of nutrients important in brain function in phenylketonuria: a systematic review and meta-analysis.

Authors:  Gina A Montoya Parra; Rani H Singh; Aysun Cetinyurek-Yavuz; Mirjam Kuhn; Anita MacDonald
Journal:  Orphanet J Rare Dis       Date:  2018-06-26       Impact factor: 4.123

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.